GlaxoSmithKline | GSK - Interest Expense On Debt


GlaxoSmithKline reported GBP188M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Alcon AG USD 54M 3M Dec/2025
Amgen USD 653M 32M Dec/2025
argenx SE USD 828K 165K Dec/2025
AstraZeneca USD 484M 181M Dec/2025
Bayer EUR 675M 87M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Fresenius EUR 81M 5M Sep/2025
Fresenius Medical Care EUR 85M 8.1M Dec/2025
Galapagos EUR 1.72M 940K Sep/2025
Genmab DKK 10M 27M Dec/2025
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
GRIFOLS EUR 141.43M 61.28M Jun/2025
Hikma Pharmaceutical USD 67M 47M Dec/2025
Lonza CHF 84M 14M Jun/2025
Merck EUR 121M 5M Dec/2025
Merck USD 412M 85M Dec/2025
Novartis USD 304M 23M Dec/2025
Novo Nordisk DKK 1.53B 3.43B Sep/2025
Orion EUR 600K 600K Sep/2025
Pfizer USD 711M 59M Dec/2025
Philips EUR 109M 31M Dec/2025
Recordati EUR 22.13M 1.43M Dec/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR -25M 252M Dec/2025
Smith & Nephew USD 69M 1000K Dec/2025
UCB EUR 49M 29M Dec/2025